GENETIC ANALYSIS |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.64 NOK | -4.48% |
|
+18.52% | -24.71% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 159.6 | 51.58 | 35.83 |
| Enterprise Value (EV) 1 | 115.8 | 35.38 | 26.96 |
| P/E ratio | -5.52 x | -1.83 x | -1.37 x |
| Yield | - | - | - |
| Capitalization / Revenue | 11.9 x | 2.49 x | 1.55 x |
| EV / Revenue | 8.65 x | 1.71 x | 1.16 x |
| EV / EBITDA | -4.07 x | -1.26 x | -1.13 x |
| EV / FCF | -5.73 x | -3.77 x | -2.85 x |
| FCF Yield | -17.4% | -26.5% | -35.1% |
| Price to Book | 2.21 x | 1.17 x | 1.01 x |
| Nbr of stocks (in thousands) | 24,916 | 24,916 | 42,157 |
| Reference price 2 | 6.407 | 2.070 | 0.8500 |
| Announcement Date | 4/21/22 | 4/20/23 | 4/18/24 |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 5.42 | 17.83 | 7.537 | 13.38 | 20.75 | 23.16 |
| EBITDA 1 | -19.47 | -6.651 | -20.57 | -28.46 | -28.17 | -23.79 |
| EBIT 1 | -19.94 | -6.749 | -20.77 | -28.87 | -28.18 | -23.92 |
| Operating Margin | -367.88% | -37.85% | -275.56% | -215.8% | -135.84% | -103.28% |
| Earnings before Tax (EBT) 1 | -22.47 | -6.937 | -22.14 | -29.01 | -28.27 | -23.82 |
| Net income 1 | -22.47 | -6.937 | -22.14 | -29.01 | -28.27 | -23.82 |
| Net margin | -414.5% | -38.9% | -293.7% | -216.8% | -136.28% | -102.82% |
| EPS 2 | -1.962 | -0.6060 | -1.289 | -1.160 | -1.130 | -0.6200 |
| Free Cash Flow 1 | -13.71 | -14.45 | -4.811 | -20.19 | -9.388 | -9.473 |
| FCF margin | -252.94% | -81.05% | -63.83% | -150.9% | -45.25% | -40.89% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 6/27/19 | 7/3/20 | 5/27/21 | 4/21/22 | 4/20/23 | 4/18/24 |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 |
|---|---|---|
| Net sales 1 | - | 3.47 |
| EBITDA | - | - |
| EBIT 1 | - | -7.777 |
| Operating Margin | - | -224.12% |
| Earnings before Tax (EBT) | - | - |
| Net income | -6.684 | - |
| Net margin | - | - |
| EPS | -0.2700 | - |
| Dividend per Share | - | - |
| Announcement Date | 11/1/22 | 2/17/23 |
1NOK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 18.1 | 0.03 | 21.3 | 43.9 | 16.2 | 8.87 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -13.7 | -14.5 | -4.81 | -20.2 | -9.39 | -9.47 |
| ROE (net income / shareholders' equity) | -53.4% | -19.3% | -55.2% | -48.9% | -48.7% | -62.6% |
| ROA (Net income/ Total Assets) | -25.2% | -9.17% | -25.6% | -25.9% | -23.8% | -25.4% |
| Assets 1 | 89.14 | 75.68 | 86.3 | 111.8 | 118.7 | 93.91 |
| Book Value Per Share 2 | 3.370 | 2.930 | 2.720 | 2.890 | 1.770 | 0.8400 |
| Cash Flow per Share 2 | 1.770 | 0.3500 | 1.410 | 1.880 | 1.020 | 0.4300 |
| Capex 1 | 0.76 | 0.08 | 0.02 | 0.08 | 0.23 | 0.14 |
| Capex / Sales | 14.05% | 0.47% | 0.31% | 0.63% | 1.09% | 0.62% |
| Announcement Date | 6/27/19 | 7/3/20 | 5/27/21 | 4/21/22 | 4/20/23 | 4/18/24 |
1NOK in Million2NOK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -24.71% | 2.44M | |
| -17.89% | 8.25B | |
| +39.20% | 3.57B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -12.61% | 1.81B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B |
- Stock Market
- Equities
- GEAN Stock
- Financials Genetic Analysis
